In efforts to bring faster, cheaper and more sensitive disease detection and DNA identification that can be done at the point-of-care, QuantuMDx (Newcastle, England) has signed an exclusive license agreement with advanced materials architect Nanosys (Palo Alto, CA) for several patents and patent applications related to the use of nanostructures for biosensors. The core intellectual property involves the use of nanowire and nanotubes in biosensors, including field effect transistor (FET) biosensors.
Under the terms of the agreement, QuantuMDx has secured exclusive worldwide rights for the use of nanostructures for DNA sequencing as well as detecting nucleic acid biomarkers associated with disease. In exchange, Nanosys has received an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.
Nanosys owns an extensive IP portfolio in nanotechnology, including quantum dots and nanowires for diverse applications, with a primary focus on LED backlighting and energy storage. QuantuMDx will use the exclusive access to these nanowire composition, synthesis and use patents, along with its proprietary molecular biology, chemistry and microfluidic technologies in a series of portable devices for molecular diagnostics and DNA sequencing. Nanosys’ technology enables accurate diagnosis and quantification of multiple biomarkers using small arrays of biosensors for diagnostic devices with numerous medical, veterinary and military applications.
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!